Several serologic biomarkers such as TNFR1, ST2, and Reg3α have been identified and were recently validated to guide risk-adapted therapy at the onset of acute GVHD in a prospective multicenter study28. The gene discussed is REG3A; the disease is acute graft versus host disease.